12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Eflornithine: Phase III started

Cancer Prevention began the double-blind, U.S. Phase III PACES trial to compare 500 mg oral eflornithine once daily plus 150 mg oral sulindac once daily vs....

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >